| Genome-wide Methylation Analysis and Validation of Cancer Specific Biomarker of Head and Neck Cancer |
|
Jae Won Chang;Ki Wan Park;So Hye Hong;Seung Nam Jung;Li hua Liu;Jin Man Kim;Tae jeong Oh;Bon Seok Koo |
| 전장유전체수준 메틸레이션 분석을 통한 두경부암 특이 메틸레이션 바이오마커의 발굴 |
|
장재원;박기완;홍소혜;정승남;류려화;김진만;오태정;구본석 |
|
|
|
|
| Abstract |
|
Methylation of CpG islands in the promoter region of genes acts as a significant mechanism of epigenetic gene silencing in head and neck squamous cell carcinoma (HNSCC). DNA methylation markers are particularly advantageous because DNA methylation is an early event in tumorigenesis, and the epigenetic modification, 5-methylcytosine, is a stable mark. In the present study, we assessed the genome-wide preliminary screening and were to identify novel methylation biomarker candidate in HNSCC. Genome-wide methylation analysis was performed on 10 HNSCC tumors using the Methylated DNA Isolation Assay (MeDIA) CpG island microarray. Validation was done using immunohistochemistry using tissue microarray of 135 independent HNSCC tumors. In addition, in vitro proliferation, migration/invasion assays, RT-PCR and immunoblotting were performed to elucidate molecular regulating mechanisms. Our preliminary validation using CpG microarray data set, immunohisto-chemistry for HNSCC tumor tissues and in vitro functional assays revealed that methylation of the Homeobox B5 (HOXB5) and H6 Family Homeobox 2 (HMX2) could be possible novel methylation biomarkers in HNSCC. |
| Key Words:
Genome-wide methylation analysis, Methylation biomarker, Homeobox B5 (HOXB5), H6 Family Homeobox 2 (HMX2), Head and neck squamous cell carcinoma (HNSCC) |
|
PDF Links
Full text via DOI
Download Citation
